A recent study found simple but accurate way to identify men with prostate cancer risk, even if the results of biopsy tests negative states.
The test, called the "PSA density" or PSA density is a size comparison of men with prostate cancer protein, called prostate-specific antigen.
Men who have a PSA value is high, later in life will suffer from cancer, compared with men who value her PSA is low, even if both groups have done a biopsy test and otherwise secure. Thus the results of the research reported in the cancer conference in Florida, USA.
If this test pass the test method to the scientists, is expected to increase the life expectancy of men with chronic cancer and avoid a biopsy examination continued. Prostate cancer is a disease that became the scourge of older men. In the U.S. alone, there were 27 thousand men die of this cancer.
Examinations are generally conducted by physicians for the detection of cancer is a biopsy. Approximately one million men in the U.S. do a biopsy test every year. Unfortunately, the success of a biopsy test to find signs of cancer, only 20-30 percent. Presumably because the sample used only a few glands. For further study, doctors usually recommend a biopsy to test again.
In a study carried out by Dr Mark Garzotto and his colleagues from Oregon Health & Science University Cancer Institute, he did a test on 511 patients who had attended a biopsy test and otherwise negative. In fact 112 people remain affected by cancer, 52 of which were malignant and deadly.
Garzoto and his colleagues found that "PSA density" is the best way to compare between the men in groups at high risk and low risk groups.
After two years of testing, 23 percent of men in high risk groups affected by cancer, while men from low-risk group, only four percent of those suffering from cancer. Lapse of four years, the figure rose to 36 percent for high-risk groups, and only nine percent for low-risk group.
The test, called the "PSA density" or PSA density is a size comparison of men with prostate cancer protein, called prostate-specific antigen.
Men who have a PSA value is high, later in life will suffer from cancer, compared with men who value her PSA is low, even if both groups have done a biopsy test and otherwise secure. Thus the results of the research reported in the cancer conference in Florida, USA.
If this test pass the test method to the scientists, is expected to increase the life expectancy of men with chronic cancer and avoid a biopsy examination continued. Prostate cancer is a disease that became the scourge of older men. In the U.S. alone, there were 27 thousand men die of this cancer.
Examinations are generally conducted by physicians for the detection of cancer is a biopsy. Approximately one million men in the U.S. do a biopsy test every year. Unfortunately, the success of a biopsy test to find signs of cancer, only 20-30 percent. Presumably because the sample used only a few glands. For further study, doctors usually recommend a biopsy to test again.
In a study carried out by Dr Mark Garzotto and his colleagues from Oregon Health & Science University Cancer Institute, he did a test on 511 patients who had attended a biopsy test and otherwise negative. In fact 112 people remain affected by cancer, 52 of which were malignant and deadly.
Garzoto and his colleagues found that "PSA density" is the best way to compare between the men in groups at high risk and low risk groups.
After two years of testing, 23 percent of men in high risk groups affected by cancer, while men from low-risk group, only four percent of those suffering from cancer. Lapse of four years, the figure rose to 36 percent for high-risk groups, and only nine percent for low-risk group.
0 comments:
Post a Comment